(Q41060627)

26 September 2017

Inhibition of human and duck hepatitis B virus by 2',3'-dideoxy-3'-fluoroguanosine in vitro (English)

1 reference

26 September 2017

1 reference

Schröder I

1

1 reference

26 September 2017

Holmgren B

series ordinal

2

1 reference

26 September 2017

Oberg M

series ordinal

3

1 reference

26 September 2017

Löfgren B

series ordinal

4

1 reference

26 September 2017

1 January 1998

1 reference

26 September 2017

1 reference

26 September 2017

37

1 reference

26 September 2017

1

1 reference

26 September 2017

57-66

1 reference

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Enhanced in vitro inhibition of HIV-1 replication by 3'-fluoro-3'-deoxythymidine compared to several other nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

A cell culture assay for compounds which inhibit hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

2',3'-dideoxy-3'-fluoroguanosine inhibits duck hepatitis B virus in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Comparative inhibition of hepatitis B virus DNA polymerase and cellular DNA polymerases by triphosphates of sugar-modified 5-methyldeoxycytidines and of other nucleoside analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Inhibition of hepatitis B virus production by modified 2',3'-dideoxy-thymidine and 2',3'-dideoxy-5-methylcytidine derivatives. In vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Inhibition of duck hepatitis B virus infection by lysosomotropic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Infection and uptake of duck hepatitis B virus by duck hepatocytes maintained in the presence of dimethyl sulfoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Comparative sequence analysis of duck and human hepatitis B virus genomes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2897%2900057-0

7 January 2021

10.1016/S0166-3542(97)00057-0

Identifiers

DOI

1 reference

26 September 2017

1 reference